HUTCHMED Says FDA Grants Sovleplenib Orphan Drug Designation
The FDA granted orphan drug designation to HUTCHMED’s sovleplenib for autoimmune hemolytic anemia.
The FDA granted orphan drug designation to HUTCHMED’s sovleplenib for autoimmune hemolytic anemia.